None listed
Conditions
Brief summary
Currently treatment for patients with longstanding chest pain caused by blockage of the blood supply to the heart is often ineffective. This trial will be to see if a spray under the tongue of a cannabis extract will help to relieve their pain. It is already used for chronic pain associated with cancer.
Interventions
In this initial trial the treatment group will be patients admitted to Waikato Hospital Emergency Department or Cardiology department, who are known to suffer from intractable coronary disease.
They will score their pain from 1-10 on a Numeric Rating Scale (NRS) and be given a single oromucosal spray dose of Sativex up to every 4 hours for a max of 5 days their NRS pain score will then be recorded one hour after receiving the dose.
Each 100 microlitre Sativex spray contains:
2.7 mg delta-9-te
In this initial trial the treatment group will be patients admitted to Waikato Hospital Emergency Department or Cardiology department, who are known to suffer from intractable coronary disease. They will score their pain from 1-10 on a Numeric Rating Scale (NRS) and be given a single oromucosal spray dose of Sativex up to every 4 hours for a max of 5 days their NRS pain score will then be recorded one hour after receiving the dose. Each 100 microlitre Sativex spray contains: 2.7 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD). Each ml contains: 38-44 mg and 35-42 mg of two extracts (as soft extracts) from Cannabis sativa L., folium cum flore (Cannabis leaf and flower) corresponding to 27 mg delta-9-tetrahydrocannabinol and 25 mg cannabidiol. Extraction solvent: Liquid carbon dioxide. Excipient(s) with known effect: each 100 microlitre spray also contains up to 0.04 g ethanol.
Sponsors
Dr Adrian Owen
Study design
Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
In this initial trial the treatment group will be patients admitted to Waikato Hospital Emergency Department or Cardiology department, who are known to suffer from intractable coronary disease
Exclusion criteria
– Hypersensitivity to cannabinoids – History of Schizophrenia – Pregnant or breast feeding mothers
Outcome results
None listed